Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results
Date:5/12/2008

MAP Pharmaceuticals. "For our Unit Dose Budesonide program for pediatric asthma, we initiated our first Phase 3 clinical trial and reported positive results from a Phase 2 pharmacokinetic trial comparing UDB to the currently marketed conventional nebulized budesonide. For our MAP0004 migraine program, we received a special protocol assessment (SPA) from the FDA, conducted investigator meetings and initiated clinical sites. We are working on manufacturing and qualification of clinical supplies with our external commercial manufacturing partners and upon completion of this work we expect to initiate this Phase 3 trial. Finally, we reported positive results from yet a third clinical program in a Phase 2a trial for MAP0005, a combination steroid and beta agonist product candidate."

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to our MAP0004 migr
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 Crosley Law Firm is proud to ... have been named to the list of Super Lawyers in ... of personal injury law. , Before receiving the designation ... selection process. First, they must come highly recommended by a ... noteworthy achievement during the past year by obtaining certain honors, ...
(Date:9/15/2014)... September 16, 2014 “Advanced First Aid for ... author Frank O’ Connor leads readers from occupational first aid ... first aid without any difficulty. There are over 165 photographs ... skill sets. , This book is an ideal reference ... course manual. It is in essence three books in one. ...
(Date:9/15/2014)... the University of Copenhagen have gained new knowledge ... The findings have recently been published in the ... The defining symptoms of Parkinson,s disease are slow ... no cure for the condition, so it is ... to shed some light on this terrible disruption ...
(Date:9/15/2014)... 2014)The Global Health Innovative Technology Fund (GHIT Fund), ... Japanese know-how and investment to the global fight ... totaling US$15.3 million to speed the development of ... diseasesmalaria, dengue and Chagas disease. The announcement marks ... since November 2013totaling $33.5 millionaimed at diseases that ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 College of Osteopathic ... recently sat in the lobby of Western University of Health ... Gomez. He asked Gomez about his medications, his blood pressure ... “He’s helping me a lot. He’s a good man,” Gomez ... student doctor and patient are part of the Longitudinal Chronic ...
Breaking Medicine News(10 mins):Health News:Thomas A. Crosley and R. Andrew Rodriguez Named 2014 Super Lawyers 2Health News:Frank O'Connor's new book explains importance of occupational and advanced first aid 2Health News:Researchers debunk myth about Parkinson's disease 2Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 2Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 3Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 4Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 5Health News:COMP Takes the Long View of Health Care 2Health News:COMP Takes the Long View of Health Care 3Health News:COMP Takes the Long View of Health Care 4
... collaboration between researchers at the Salk Institute for Biological ... the tumor suppressor p53, long thought of as the ... cancer-causing mutations. It may also prevent established cancer cells ... serving as a "Guardian against Genome Reprogramming." The ...
... St. Louis and a woman in New Hampshire have received ... program of the Organ Procurement and Transplantation Network (OPTN) that ... candidates with living donors. Both recipients Ken Crowder of ... loved ones who were willing to donate a kidney but ...
... discrimination among Mexican and Mexican American students from Phoenix-area ... stress when trying to acculturate with mainstream U.S. culture, ... experienced acculturation stress related to discrimination, they were at ... The study is in the December issue of ...
... , MONDAY, Dec. 13 (HealthDay News) -- A federal judge ... unconstitutional, saying the federal government has no authority to require ... a cornerstone of the new legislation, signed into law in ... not unexpected, and both supporters and opponents of the legislation ...
... million men and women ages 50 to 64 stand ... that expand access to affordable health insurance, assure that ... insurers from denying coverage or charging higher premiums to ... limits in health insurance policies, according to a new ...
... the activity of genes direct changes to the DNA ... genes are switched on and off, called epigenetic means. Tumor-suppressor ... for the cancerous growth of cells. Researchers at the ... on a genome-wide scale in cases of ovarian cancer. ...
Cached Medicine News:Health News:The stemness of cancer cells 2Health News:The stemness of cancer cells 3Health News:2 people receive kidney transplants in pilot program using CMU software 2Health News:2 people receive kidney transplants in pilot program using CMU software 3Health News:Drug use and discrimination among Phoenix area Mexican heritage youth 2Health News:Drug use and discrimination among Phoenix area Mexican heritage youth 3Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:18.3 million baby boomers could benefit from the Affordable Care Act 2Health News:18.3 million baby boomers could benefit from the Affordable Care Act 3Health News:18.3 million baby boomers could benefit from the Affordable Care Act 4Health News:Ovarian cancer advances when genes are silenced 2
(Date:9/15/2014)... /PRNewswire-iReach/ -- Asthma is a chronic inflammatory lung ... most commonly starts in childhood. It is a ... airways, leading to airflow limitation and airway hyper-responsiveness ... endogenous and exogenous irritants. Exposure to irritants instigates ... the airways, tightening of the respiratory muscles, and ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne Medical Response, ... services, has been selected by Inc. Magazine as ... America. Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... list identifies successful, privately-held companies with the largest ... Response, one of only two ambulance companies to ...
(Date:9/15/2014)... Nev. , Sept. 15, 2014 PDL BioPharma, ... that it has paid the September 12, 2014, regular quarterly ... owning shares of PDL as of September 5, 2014, the ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... to Prevent,and Reverse Atherosclerotic Heart Disease, EMERYVILLE, Calif., ... drug discovery and development company, announced,today the first ... in animals through the pathway known as reverse ... by which excess,cholesterol can be removed from tissues ...
... 14, 2007 - Acceleron Pharma,Inc., a biopharmaceutical ... metabolic and cancer-related,diseases, today announced results of ... ability of the compound to increase,muscle mass ... murine models of,muscular dystrophy. ACE-031 inhibits negative ...
Cached Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
Cloward cervical retractor. Size 18 mm....
Large, removable blades, length 242 mm, (9 1/2"). Function: tissue retracting....
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
Medicine Products: